The Chinese herbal formula Huoxiang Zhengqi for atopic dermatitis with dampness pattern (CHARM): a study protocol for a double-blinded randomized controlled trial

Meiling Xuan1,2, Xiaohui Guo1,2, Hongyi Li3, Ting Xie3, Xiumei Mo3 and Zehuai Wen1,2*

Abstract

Background: Atopic dermatitis (AD) is a complex, common inflammatory skin disease. The Chinese herbal formula Huoxiang Zhengqi (HXZQ) has been a common dermatosis treatment in China for many years, but there is no high-level evidence for its effect on AD/eczema. The aim of this trial is to examine the efficacy and safety of HXZQ treating AD/eczema patients.

Methods: This is a double-blind, multi-center, randomized controlled trial comparing HXZQ to a placebo. It will consist of 4 weeks’ treatment and 4 weeks of follow-up. A total of 218 participants will be randomly allocated into two groups—an HXZQ group and a placebo group, from 7 hospitals in China. Patients diagnosed with AD will be enrolled if they are in accordance with CM dampness pattern, have body surface area (BSA) of 1–10%, have investigator’s global assessment (IGA) of 1–3, have age between 18 and 70 years, and provide signed informed consent. The Eczema Area and Severity Index (EASI) is the primary outcome. The secondary outcomes are the numerical itch rating scale, IGA, BSA, Skindex-29, and EQ-5D-5L score, from baseline to the end of the treatment. Analysis will be on intention-to-treat and per-protocol subject analysis principles.

Discussion: The goal of this trial is to evaluate the efficacy and availability of HXZQ oral liquid in treating AD/eczema in terms of symptoms and eczematous lesions. It will also address whether it has positive effect on QoL.

Trial registration: Chinese Clinical Trial Registry (http://www.chictr.org.cn/index.aspx): Chinese herbal formula Huoxiang Zhengqi for atopic dermatitis with dampness pattern (CHARM): a double-blinded randomized controlled trial, ChiCTR1900026700. Registered on 19 October 2019.

Keywords: Atopic dermatitis, Eczema, Randomized controlled trial, Huoxiang Zhengqi, Chinese medicine
Background
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by intense itching and eczematous lesions. It diminishes quality of life and incurs high healthcare costs. AD prevalence has increased in recent decades in China, varying between 0.70% (among children) and 8.3% (among teenagers) [1]. A recent survey has reported that the prevalence of AD among adults was 4.6%, nearing rates for childhood [2].

Moisturizing and basic care are the cornerstone of AD management. A systematic review has shown that moisturizers prolong time to flare-up and reduce topical corticosteroid (TCS) use, thus mitigating the effects of atopic eczema [3]. Topical daily use of moisturizers has also been shown to be tolerated by patients, and to improve treatment of mild to moderate adulthood AD [4]. It has been established that systemic therapies are options for patients with moderate-to-severe AD for whom first-line therapies are ineffective [5]. However, there are limited options for prescription topical therapy for AD. TCSSs are used in the management of AD and are the mainstay of anti-inflammatory therapy. In addition, some side effects, such as skin atrophy, will resolve after discontinuing TCS use, but this may take months. Given the recommendations from the guidelines, continuous application of TCS over extended durations should be avoided [6]. Chinese herbal medicine (CHM) has been a common treatment for symptoms of AD in China for centuries. Findings from a systematic review have suggested that Chinese herbal medicine mitigates AD and does not cause severe adverse events [7].

The Chinese herbal formula Huoxiang Zhengqi (HXZQ) is a classical prescription. It was documented by the Prescriptions People’s Welfare Pharmacy (Taiping Huimin Hejiju Fang), a Song Dynasty government in the early twelfth century. It is a dampness-dispelling formula composed of Pericarpium Arecae (Dafupi), Radix Angelicae Dahuricae (Baizhi), Perillae (Zisu), Poria (Fuling), Rhizoma Pinelliae (Banxia), Rhizoma Atractylodis Macrocephala (Baizhu), Pericarpium Citri Reticulatae (Dafupi), Cortex Magnoliae Officinalis (Houpu), Radix Platycodonis (Jigeng), Herba Pogostemonis (Huoxiang), and Radix Glycyrrhizae (Gancao). It has been used to treat various diseases (gastrointestinal cold and acute gastroenteritis) associated with the dampness pattern (Shi Zheng) in Chinese medicine (CM). It has had an exceptional safety profile over hundreds of years [8]. At present, it is an over-the-counter (OTC) medication recorded in the Chinese Pharmacopoeia 2015 edition, and it comes in many dosage forms, such as capsules, boluses, pills, and liquids [9]. Pharmacological studies have shown that HXZQ and its pharmaceutical ingredients have antispasmodic, antibacterial, antiallergic, immunity-enhancing effects, both in vivo and vitro [10–13]. HXZQ liquid has obvious inhibitory effect on Staphylococcus aureus in vitro. HXZQ liquid drug-serum may neutralize and block IgE and has inhibitive effects on degranulation of cells when resensitized by antigens. Besides, it can block allergic response type I [14]. There is positive effect of HXZQ on immune and metabolic functions, intestinal flora disturbance of rat model with the dampness pattern (Shi Zheng) in CM [15–17]. Thus far, it is shown that Staphylococcus aureus colonization is a characteristic of skin lesions and drives inflammation in AD [18–20]. In the composition of HXZQ, most of the pogostone (main components of Herba Pogostemonis) and its derivatives, Perillae extract, Cortex Magnoliae Officinalis, Hesperidin (the main active composition of Pericarpium Citri Reticulatae) possess different levels of antibiotic activities, in which mainly against Staphylococcus aureus [21–26]. Since being on the market, it also has a good safety record [8]. In recent years, several case reports and observational studies have reported that oral administration and external use of HXZQ formula can relieve itching and lesions in AD and eczema adult and child patients [27–31].

AD is the most commonly used term for the condition it describes; eczema is another term often used by patients and physicians alike [32]. However, the nomenclature for AD remains controversial. In China, AD and eczema have two separate sets of guidelines. The diagnostic criteria in the AD guidelines are based on the presence of several essential and associated features, which are recommended by the Williams diagnostic criteria. Eczema diagnosis relies primarily on clinical presentation, eczematous lesions such as erythema, papules, blisters, lichenification, infiltration, and pruritus. In CM theory, dampness is a dominant syndrome in AD/eczema’s pathogenesis and disease progression. Previous clinical practice on diseases with the dampness pattern, such as AD/eczema, has shown some improvement in symptoms. However, to date, there is no evidence based on research using a placebo as control. This multi-center, randomized double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of HXZQ in adults with AD/eczema in China.

Methods/design
Design and setting
This is a multi-center, double-blinded, randomized controlled trial (RCT), which will be conducted in 7 third-grade first-class hospitals in China. The study aims to enroll 218 patients with eczema over a 3-year period. Patients will be randomized at a ratio of 1:1 to receive either HXZQ oral liquid (20 ml twice daily) or a placebo. A 4-week follow-up period will continue until the study ends. This trial was approved by the seven sites’ ethics
committees and required archival filing management with six other sites’ ethics committees. A flow diagram of the trial is shown in Fig. 1, and the schedule of enrolment, intervention, and assessments is presented in Table 1.

**Participants**

**Recruitment**
Participants will be recruited through social media, advertisements in local newspapers, or posters in hospitals. Some participants may spontaneously contact research centers.

**Inclusion criteria**
Patients will be enrolled if they have been diagnosed with eczema, and in accordance with the CM pattern criteria for dampness. They must be between 18 and 70 years of age, have $1\% < \text{body surface area (BSA)} < 10\%$, have $1 \leq \text{investigator’s global assessment (IGA)} \leq 3$, and provide signed informed consent.

**Exclusion criteria**
1. Those with any uncontrolled cardiovascular, respiratory, digestive, urinary, or hematological disease; known cancer or mental illness
2. Those who have ever used HXZQ for treating eczema
3. Anyone allergic to any medicine or ingredients used in the study
4. Those whose examination results show alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 2 times the upper limit normal value; or total bilirubin or blood urea nitrogen (BUN) level exceeds 1.5 times the upper limit normal value during the screening period

![Fig. 1 Study flow chart](image)
5. Women who are pregnant or lactating or who plan to become pregnant within 3 months
6. Medication used: (1) systemic therapy with immunomodulatory or immunosuppressive agents (including *Tripterygium wilfordii*) within the previous 4 weeks; (2) topical or systematic therapy with antibiotics or antihistamines within the previous 2 weeks; (3) phototherapy (such as PUVA, UVA, or UVB) within the previous 4 weeks; (4) topical therapy with immunomodulator within the previous 4 weeks.

### Table 1: Schedule of enrollment, treatment, and assessment

| TIMEPOINT             | Enrollment | Allocation | Treatment period | Follow-up period |
|-----------------------|------------|------------|------------------|------------------|
|                       | 0          |            | 2\textsuperscript{nd} week | 4\textsuperscript{th} week | 8\textsuperscript{th} week |
| **ENROLLMENT:**       |            |            |                  |                  |
| Eligibility screen    | ▲          |            |                  |                  |
| Chinese Medicine      | ▲          |            |                  |                  |
| pattern               |            |            |                  |                  |
| Informed consent      | ▲          |            |                  |                  |
| Randomization         | ▲          |            |                  |                  |
| **INTERVENTIONS:**    |            |            |                  |                  |
| HXZQ oral liquid      | ▲          |            |                  |                  |
| Placebo               | ▲          |            |                  |                  |
| **ASSESSMENTS:**      |            |            |                  |                  |
| Examination tests     | ▲          |            |                  |                  |
| Demographics          | ▲          |            |                  |                  |
| Vital signs           | ▲          |            |                  |                  |
| Medical history       | ▲          |            |                  |                  |
| Chinese Medicine      | ▲          | ▲          | ▲                | ▲                |
| symptoms              |            |            |                  |                  |
| EASI                  | ▲          | ▲          | ▲                | ▲                |
| BSA                   | ▲          | ▲          | ▲                | ▲                |
| NRS, IGA              | ▲          | ▲          | ▲                | ▲                |
| Skindex-29, EQ-5D-5L  | ▲          | ▲          | ▲                | ▲                |
| Drug recall           | ▲          |            |                  |                  |
| Patient’s diary       | ▲          | ▲          | ▲                | ▲                |
| Adverse event         | ▲          | ▲          | ▲                | ▲                |
| Drug combination      | ▲          | ▲          | ▲                | ▲                |
previous 2 weeks; or (5) topical or systematic use of any over-the-counter drugs within the previous week.

7. Those who are participating in any other clinical trial or had participated in a clinical trial within the previous month.

8. Those who are considered unfit for the trial.

CM pattern differentiation criteria
The CM pattern diagnostic criteria will follow the Criteria of Diagnosis and Therapeutic Effect and Syndromes in Traditional Chinese Medicine (issued by the National Administration of Traditional Chinese Medicine, China) and the Textbook of Diagnostics of Traditional Chinese Medicine [33]. CM pattern will be judged by senior deputy chief physician during screening period. The dampness pattern should meet two major symptoms or one major symptom with one secondary symptom.

- Major symptoms: mental fatigue, anorexia, loose stool or watery diarrhea, white sticky greasy tongue coating
- Secondary symptoms: heavy sensation in limbs, abdominal distension, pale tongue or pale teeth-marked tongue, soggy pulse or moderate pulse

Interventions
Patients in the experimental group will receive HXZQ oral liquid, 20 ml twice daily, for 4 weeks. Placebo liquid will be given to patients in the control group 20 ml twice daily, for 4 weeks. The placebo will consist of glycyrrhizin, bitterant, caramel color, and trace amounts of cinnamon extract and ginger juice. It will be consistent with the HXZQ oral liquid in appearance, taste, and weight, to the greatest extent possible. The HXZQ and placebo oral liquids will be manufactured by Taiji Group Chongqing Fuling Pharmaceutical Co. Ltd. (Chongqing, China) according to the requirements of the good manufacturing practice, and will be met the hygienic requirements of the oral liquid product.

Rescue and concomitant treatment
Routine treatment, such as urea ointment, is recommended for each group, on nonlesional skin, based on doctors’ recommendations. In cases of serious itching, cetirizine hydrochloride or levocetirizine is to be used as a rescue drug, and dosage and frequency are to be recorded for each use.

Randomization and blinding
Eligible patients will be enrolled at each site. The participants will be randomly allocated to either the HXZQ group or the placebo group at a 1:1 ratio through an interactive web response system (IWRS). A computer-generated random list for center-stratified method and permuted block size will be used in IWRS and performed by the Institute of Basic Research in Clinical Medicine (IBRCM), China Academy of Chinese Medical Science with SAS 9.2 (SAS Institute Inc., Cary, USA).

The randomization results and blinding codes will be kept strictly confidential; they will be concealed until interventions are all assigned, and enrollment, follow-up, data collection, data cleaning, and analysis are complete. Participants and researchers, including paramedics, investigators, outcomes assessors, and statisticians, will be unaware of the allocation.

Outcome measures
The primary outcome is change in the Eczema Area and Severity Index (EASI) scores from baseline to the end of the 4th week. The EASI is a composite index recommended by the global Harmonising Outcome Measures for Eczema (HOME) as the core outcome measurement instrument for AD [34]. It includes an assessment of disease extent and body surface area, converted to a proportional factor (on a scale of 0–6), for four body regions (head/neck, upper limbs, trunk and lower limbs).

In this trial, the proportions are 10% for head and neck, 20% for upper extremities, 30% for trunk, and 40% for lower extremities. It also includes an assessment of erythema, infiltration and/or papulation, excoriation, and lichenification (on a scale of 0–3 for each one). The total EASI score is the sum of these four body-region scores and the range from 0 to 72 [35].

Secondary outcome measurements are the change in the pruritus numerical rating scale (NRS) of itch, IGA, BSA, Skindex-29, and EQ-5D-5L score from baseline to the end of the treatment period.

The pruritus NRS is a scale from 0 to 10, which assess the pruritus intensity (0 = no itch and 10 = worst itch imaginable). IGA scale uses clinical characteristics to assess overall appearance of the lesions at a given time point (0 = clear; 1 = almost clear; 2 = mild, but noticeable; 3 = moderate; 4 = severe; 5 = very severe). BSA refers the total surface area of the human body. BSA of lesional involvement in-of-itself is also an important aspect of AD severity. Hand surface area (HSA) will be used to guide the assessment of involved surface area. HAS represents 1% of the total body surface area [36]. Skindex-29 is one of the best dermatological instruments for measuring dermatology-specific quality of life (QoL). It is a 30-item dermatology-specific QoL instrument for adults with an unscored item no.18, measuring 3 domains—emotions, functioning, and symptoms. Each item is rated on a 5-point Likert scale (never, rarely, sometimes, often, all the time), with higher scores indicating worse health status. And the EQ-5D is a generic instrument for describing and valuing health. It defines health in terms of 5
dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression [37]. The 5-level version of the EQ-5D (EQ-5D-5L) will be used as secondary outcome in this trial.

EASI50 and EASI75 are regarded as secondary outcomes as well. EASI50 and EASI75 refer to an EASI score showing improvement exceeding 50% and 75%, respectively, during the treatment period [13]. Antihistamine use will be recorded at baseline, week 2, week 4, and week 8. CM syndrome and tongue and pulse condition will be assessed at the beginning and at the end of the study.

Safety assessment
Adverse events (AEs) that occur during this trial will be recorded and reported to investigators, and the causality between AE and intervention will be assessed according to the WHO Uppsala Monitoring Centre System for Standardized Case Causality Assessment [38]. An independent data and safety monitoring committee will assess any safety data requested during the trial. Investigators will address AEs using the IWRS in a timely manner in cases of emergency. They will apply to break the blindness if necessary.

Sample size calculation
Based on Belloni et al.’s study [39], MAS063D (Atopicleair) used to manage mild to moderate AD can achieve a 4 point improvement in EASI score over a 22-day period. A systematic review showed that EASI score in the oat moisturizer group was 4.38 points lower than that of the vehicle or no treatment groups [3]. The minimal important difference (MID) of EASI is 3.4, and it is hypothesized that EASI change in HXZQ oral liquid therapy for AD/eczema from baseline is 4.8 less than placebo. According to this hypothesis, and as calculated by PASS 11.0 (NCSS, LLC; Kaysville, Utah, USA), a sample size of 92 for each group can achieve 90% power and thus rule out a two-sided type I error of 5%. In this way, it can detect a superiority margin difference of 4.8 (standard deviation, SD = 3) for this two-arm trial with equal allocation in each group. Considering a 15% loss to follow-up, the total sample size should be adjusted to 218.

Statistical analysis
Data analysis will follow the trial’s statistical analysis plan. All data will be processed by statistical analyses with PASW Statistics 18.0 (IBM SPSS Inc., Armonk, New York, USA) and SAS 9.2 (SAS Institute Inc., Cary, USA). Two-tailed P values < 0.05 are considered statistically significant. Analysis will follow intention-to-treat and per-protocol subject principles. Missing data will be processed with the multiple imputation method. The baseline characteristics will be reported according to treatment groups. The EASI score will be compared between groups at 2 weeks and 4 weeks using a chi-square test, and considering the superiority comparison between the two groups via the 95% confidence interval method. The secondary outcomes NRS, IGA, Skindex-29, EQ-5D-5L, antihistamines use, CM syndrome, and tongue and pulse condition will be summarized with frequency, mean, standard deviation, median, and range.

At each time point, comparisons between the experimental group and the placebo group will be conducted using a t test. In order to distinguish the treatment effect and the time effect, changes from baseline in the above outcomes will be tested using repeated measure analysis of variance. Analysis of covariance or a logistic regression model will be used to adjust the central effect and covariates such as sex, age, disease course, atopic history, EASI, IGA, and BSA at the baseline. The last observation carried forward and multiple imputation method will be used to handle the missing data of continuous variables.

All investigators and study assistants will also be provided with written protocol documents. The data from all of the sites will be checked regularly by researchers and overseen by monitors. The trial’s monitoring tasks will be entrusted to Beijing Yaohai Ningkang Pharmaceutical Technology Co. Ltd. The auditing and inspection of the trial will be performed by the department of science research at the Guangdong Provincial Hospital of Chinese Medicine and the Office of the National Key Research and Development Program of China. The data monitoring committee will assess the safety data and the critical efficacy outcomes.

A transportation allowance will be provided to the participants for return visit. The disease severity evaluation and QoL measurement take approximately 15–30 min. Participants can withdraw from this trial at any time for any reason. Investigators should ask if the patient would be willing to complete the assessments when they withdraw, and record the last date the medicine was taken. Incidences of loss to follow-up and withdrawal will be recorded and reported.
Safety will be evaluated by adverse event forms, and presented with descriptive statistics for each group. The statistics will be organized by treatment phase and post-treatment phase, as appropriate, utilizing a safety analysis set. The frequency difference of adverse events between groups will be assessed by chi-square test or Fisher’s exact test. For different AE severities, a rank-sum test will be performed to analyze the independent ordered multiple category data between the two groups.

Discussion
This is a protocol for a multi-center, double blinded, randomized, placebo-controlled trial. This trial will be conducted in outpatient settings with experienced investigators, and participants will be recruited from 7 hospitals in different Chinese cities. The goal of this trial is to determine whether treatment with HXZQ oral liquid is of benefit to AD/eczema patients with the CM dampness pattern.

Syndrome differentiation is the fundamental principle of CM theory. Dampness pattern in CM is a syndrome differentiation type for atopic dermatitis and eczema. In China, HXZQ is commonly used for treating vomiting, diarrhea, the common cold, and insolation with the dampness pattern. Studies have reported this formula’s components’ bioactivity in enhancing cellular immunity, as well as its anti-allergy, antibacterial, and antiviral properties. For example, *Herba Pogostemonis* (Huoxiang), *Perillae* (Zisu), *Pericarpium Citri Reticulatae* (Houpu), and *Cortex Magnoliae Officinalis* (Chenpi), and *Cortex Magnoliae Officinalis* (Chenpi) have been reported to have different levels of antibacterial effects. This produces antagonistic action to *Staphylococcus aureus* [21, 40–44]. Since the 1990s, reports have proliferated about HXZQ for treating skin diseases (such as eczema, urticarial, and prurigo nodularis), both internally and externally [13, 45–47]. Although many cases of HXZQ application for skin diseases have been reported, most are based on clinical experience. Few randomized trial is available to determine the benefit of this formula for skin problems caused by inflammatory reactions and/or allergies. Thus, evidence from a well-designed clinical trial is needed.

One challenge of this trial is that patient screening and primary outcome evaluation requires physicians with CM and dermatology backgrounds, or collaboration between CM physicians and dermatologists. Therefore, effective communication is needed for cooperation and support throughout the trial. Thus, we will offer a training workshop before recruitment and hire a clinical research organization to assist with data monitoring and management during the trial. Another challenge for skin disease trials is patient compliance with topical medicine. We will provide detailed instructions on the basic skin management recommended by the AD and eczema guidelines. Additionally, participants will be given moisturizers and advised not to use any topical drugs in the 24 h before the hospital visits. In this way, the primary outcome EASI can be measured more objectively. In addition, research assistants will check the data integrity of the quality of life (QoL) scale. Moreover, we will provide a separate space for participants to fill out the QoL forms out of concerns for their privacy.

At the end of this trial, we expect to know HXZQ’s efficacy in treating AD/eczema with dampness pattern in terms of both symptoms and improvement in eczematous lesions. We also want to learn whether it has a positive effect on QoL.

Trial status
The protocol version is V1.1/20190826. The training workshop for the trial began in September 2019, and recruitment started in January 2020 and is meant to last until December 2021.

Abbreviations
AD: Atopic dermatitis; AE: Adverse events; AST: Alanine aminotransferase; AT: Alamine aminotransferase; BSA: body surface area; BUN: Blood urea nitrogen; CHM: Chinese herbal medicine; CM: Chinese medicine; EASI: Eczema Area and Severity Index; EQ-5D: EuroQol-5 Dimension; EQ-SD: European Quality of Life-5 Dimensions; KPS: Karnofsky perforated version; NPD: NURSE-EVA; NRS: Numerical rating scale; OTC: Over-the-counter; QoL: Quality of life; RCT: Randomized controlled trial; SD: Standard deviation; TCS: Topical corticosteroids

Acknowledgements
We thank Prof. Lingling Liu (Peking University First Hospital, China) and Prof. Fei Hao (the First Hospital Affiliated to AMU, Southwest Hospital, China) for comments on study design. We also thank Prof. Yi Liu (Chongqing Traditional Medicine Hospital, China), Prof. Shaqiong Xie (Shanghai Skin Disease Hospital, China), Prof. Hongxia Liu (Jinjiang yugur autonomous region hospital of traditional Chinese medicine, China), Prof. Xuesong Yang (Yunnan College of Traditional Chinese Medicine of the First Affiliated Hospital, China), Prof. Ling Feng (Beijing Friendship Hospital, Capital Medical University, China), and Prof. Yu Jin (the No.2 Shenzhen People’s Hospital, China) for their comments and suggestions. We also wish to thank the doctors, nurses, clinical research associates, and clinical research coordinators in all cooperative hospitals for their efforts.

Authors’ contributions
MLX: design, data collection, and manuscript writing. XHG: design, data collection, and manuscript writing. WWOY: data analysis and interpretation data, writing the manuscript, and the decision to publish the manuscript. All authors read and approved the final manuscript.

Funding
This research received a grant from the National Key Research and Development Program of China (No. 2018YFC1707407). The funding body does not take any role in this study, such as design, collection, analysis, interpretation data, writing the manuscript, and the decision to publish the results.

Availability of data and materials
The final datasets established and analyzed are not publicly available. But the corresponding author will have access to the final trial dataset and disclose contractual agreements that limit access to investigators or whom with reasonable request.
Ethics approval and consent to participate

Ethics approval for this study protocol has been obtained from the Ethics Committee of Guangdong provincial hospital of Chinese Medicine (No. BF2019-098-01/BF2019-098-02). Recruitment of other 6 centers has been approved by their ethics committee before proceeding. These are Chong Qing Traditional Medicine Hospital (No.2019(Ethics)-7), Shanghai Skin Disease Hospital (No. 2019-33); Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine (No. 2019EX022); Yunnan Provincial Hospital of Traditional Chinese Medicine (No.BG-2019-027-02); Beijing Friendship Hospital, Capital Medical University (No. 2019-P2-267-02); and No.2 Shenzhen People’s Hospital (No.2019-Y1-02P3). Informed consent will be obtained from all participants before allocation.

Consent for publication

Not applicable.

Competing interests

The authors declare they have no competing interests.

Author details

1. Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, 111 Dade Road, Guangzhou 510120, China.
2. State Key Laboratory of Dampness Syndrome of Chinese Medicine, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.
3. Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine, 111 Dade Road, Guangzhou 510120, China.

Received: 21 June 2020 Accepted: 30 December 2020

Published online: 19 January 2021

References

1. Xu F, Yan S, Li F, Cai M, Chai W, Wu M, et al. Prevalence of childhood atopic dermatitis: an urban and rural community-based study in Shanghai, China. PLoS One. 2012;7(5):e36174.
2. Wang X, Li LF. Research on the incidence and clinical characteristics of atopic dermatitis adults in third-grade first-class hospitals in China. Academic conference proceeding of Chinese association of integrative medicine in dermatology. Zhuhai, China: 2017.
3. Van Zauren EI, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Emollients and moisturisers for eczema. Cochrane Database Syst Rev. 2017;2:Cd012119.
4. Cristaudo A, Lupi F, Mariano M, Cianchini G, De Rocco M, De Pita O, et al. Clinical and instrumental evaluation of the efficacy of an emollient cream and a cleansing cream in the management of mild to moderate adulthood atopic dermatitis. J Dermatolog Treat. 2018;29(8):855–9.
5. Dhakwal G, Albrecht L, Gniadecki R, Poulin Y, Yeung J, Hong CH, et al. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section IV: treatment options for the management of atopic dermatitis. J Cutan Med Surg. 2018;22(1_suppl):21–9.
6. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–32.
7. Tan HY, Zhang AL, Chen D, Xue CC, Lenon GB. Chinese herbal medicine for atopic dermatitis: a systematic review. J Am Acad Dermatol. 2013;69(2):295–304.
8. Zhao HJ, Guo LP, Yang FW, Zhang MY, Zhang LS, Liu Z, et al. Huoxiang Zhengqi formulas for treatment of gastrointestinal type cold syndrome systematic review and meta-analysis. Zhongguo Zhong Yao Za Zhi. 2017;42(8):1486–9.
9. Commission CP. The Chinese Pharmacopoeia. 2015th ed. 2015, p. 1726.
10. Zhang HF. Pharmacology and clinical research progress of the Chinese herbal formula Huoxiang Zhengqi. Contemp Med. 2008;05(08):137–9.
11. Zeng HL, Li J. Brief introduction of the applications of the Chinese herbal formula Huoxiang Zhengqi. J Pract Tradit Chin Med. 2014;28(08):124–6.
12. Yu CX, Zhu L. Experimental researches on inhibitory effect of Huoxiang Zhengqi liquid on histamine release. Chin J Integr Tradit West Med. 2003;04:276–80.
13. Zhang H, Li S, Xiao H. Overview of the clinical application of Chinese herbal formula Huoxiang Zhengqi preparations. Hunan J Tradit Chin Med. 2018;34(03):203–5.
14. Chuanshi Y, Ling Z. Explore of immune mechanism of Huoxiang Zhengqi oral liquor restrain degranulation of mast cell. Chin Tradit Pat Med. 2002;24(02):4–5.
15. Yu H. Experimental study on Huoxiangzhengqi decoction and its drug-serum against allergic reaction [Master thesis]. Kunming: Kunming Medical University; 2006.
16. Yao L, Wei L. Effect of Huoxiang Zhengqi powder on immune and metabolic function of sub-healthy animals with dampness stagnation of spleen and stomach. Lishizhen Med Materia Med Res. 2011;22(05):1190–2.
17. Chunjuan L. Intervention of Huoxiang Zhengqi oral liquid on metabolism and intestinal flora of dampness trapped spleen syndrome [Master thesis]. Guangdong: Guangdong Pharmaceutical University; 2018.
18. Sandlinds A, Sutherland C, Irvine AD, McLean WH. Filaggrin in the frontline: role in skin barrier function and disease. J Cell Sci. 2009;122(pt 9):1285–94.
19. Grice EA, Kong HH, Corlain S, Deming CB, Davis J, Young AC, Bouffard GG, Blakesley RW, Murray PR, Green ED, Turner ML, Segre JA. Topographical and temporal diversity of the human skin microbiome. Science (New York, NY). 2009;324(5931):1190–2.
20. Kobayashi T, Glatz M, Horuchi K, Kawai K, Hiyama Y, Kaplan DH, Kong HH, Amagai M, Nagao K. Dysbiosis and Staphylococcus aureus colonization drives inflammation in atopic dermatitis. Immunity. 2015;42(4):756–66.
21. ZhengWei T. Antibacterial mechanism of patchouli ketone and its derivatives [PhD thesis]. Chengdu: Chengdu University of Traditional Chinese Medicine; 2016.
22. Choekun L. Antibacterial experimental of the chemical constituents from the water extracts Herba Pogostemonis. J Chin Med Mater. 2005;28(08):700–3.
23. Jingchen Z, Yuhua W, Chunhong P, Hansong Y, Junmei L, Lidong J, et al. Basic antimicrobial actions of Agastache rugose. Food Sci Technol. 2015;40(07):240–4.
24. Lei W, Xiao L, Xuefang B, Bingjian F, Fei C, Wei C, et al. Optimization of the ultrasonic extraction technology of total terpenoids from the leaves of perilla frutescens and study on its antibacterial activities against 10 kinds of common pathogens. China Pharm. 2018;29(16):2193–7.
25. Lai Wah C, Emily LCC, Constance LLS, Wanyu W, Paul WSH. Antimicrobial and antioxidant activities of Cortex Magnoliae Officinalis and some other medicinal plants commonly used in South-East Asia. Chin Med. 2008;3(4):1805–7.
26. Lan Z, Cheng P, Peiao Y, Yunxia L, Ruoqi Z. Research progress on in vitro antibacterial activities of some kinds of damp dispersing herbs. J Pharm Res. 2017;36(11):656–659+666.
27. Leping Q. Case report of Huoxiang Zhengqi powder used in pediatrics. J Liaoning Univ Tradit Chin Med. 2010;12(05):218–9.
28. Jing W, Xinmin L. Dr. Li Xinmin’s experience in treating child eczema with Mahuang Liangqiao Chixiaodu decoction and Huoxiang Zhengqi powder. J Pract Tradit Chin Med. 2017;33(11):1332–3.
29. Guoqin S, Xuexin W. Novel therapeutic application of Huoxiang Zhengqi liquid for skin disease. Chin J Mod Drug Appl. 2004;20(1):181.
30. Mengni H, Jun M. Clinical cases treated with Huoxiang Zhengqi formula. Jiangsu J Tradit Chin Med. 2020;52(08):59–60.
31. Ping Y, Lan G, Donghua C, Xiaoling L. Therapeutic effect of Huoxiang Zhengqi liquid for chronic eczema in paralytic patients. Today Nurse. 2018;25(11):109–11.
32. Kantor R, Thysen JP, Paller AS, Silverberg J. Atopic dermatitis, atopic eczema, or eczema? A systematic review, meta-analysis, and recommendation for uniform use of ‘atopic dermatitis’. Allergy. 2016;71(10):1480–5.
33. He JC. editor. Diagnostics of traditional Chinese medicine. Beijing: People’s Medical Publishing House Co., LTD; 2017.
34. Schmitt J, Spulki TH, Thomas KS, Simpson E, Furse M, Deckert S, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134(4):800–7.
35. Barbier N, Paul C, Luger T, Allen R, De Prost Y, Papp K, et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol. 2004;150(1):96–102.
36. Rhodes J, Clay C, Phillips M. The surface area of the hand and the palm for estimating percentage of total body surface area: results of a meta-analysis. Br J Dermatol. 2013;169(1):76–84.
37. Herdman M, Gudex C, Lloyd A, Jansen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-SD (EQ-SD-SL). Qual Life Res. 2011;20(10):1727–36.
38. WHO. The use of the WHO-UMC system for standardised case causality assessment. 2018. https://www.who-umc.org/media/164200/who-umc-causality-assessment_new-logo.pdf. Accessed June 2020.
39. Belloni G, Pinelli S, Veraldi S. A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair) in the treatment of mild to moderate atopic dermatitis. Eur J Dermatol. 2005;15(1):31–6.

40. Wang XY, Chen YY, Bao JK. Study on the molecular mechanism of pogotone against Staphylococcus aureus. Chin J Antibiot. 2018;43(06):759–64.

41. Wan F, Peng C, Cao XY, Xiong L, Wei XL, Zhou YX. Antibacterial activity and mechanism of essential oil from Pogostemon cablin against Staphylococcus aureus. Chin Tradit Pat Med. 2014;36(07):1376–81.

42. Wei L, Li X, Wang XF, Jing BN, Chen F, Cui W, et al. Optimization of the ultrasonic extraction technology of total triterpenoids from the leaves of Perilla frutescens and study on its antibacterial activities against 10 kinds of common pathogens. China Pharm. 2018;29(16):2193–7.

43. Cao MX. The latest research progress on extraction and pharmacological activities of Pericarpium Citri Reticulatae. Guide China Med. 2012;10(12):452–4.

44. Chan LW, Cheah EL, Saw CL, Weng W, Heng PW. Antimicrobial and antioxidant activities of Cortex Magnoliae Officinalis and some other medicinal plants commonly used in South-East Asia. Chin Med. 2008;3:15.

45. Guan NY. Chinese herbal formula Huoxiang Zhengqi as the treatment for tuberous pruritus in 55 cases. Hebei J Tradit Chin Med. 1998;03:160.

46. Liu YS. Huoxiang Zhengqi water as an external therapy for skin diseases. Sichuan J Tradit Chin Med. 1990(08):45.

47. Tao KG. Huoxiang Zhengqi water as an external therapy for skin diseases Shanxi. J Tradit Chin Med. 1998(09):20.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.